Cyclopropane-Containing Fatty Acids from the Marine Bacterium Labrenzia sp. 011 with Antimicrobial and GPR84 Activity

Moghaddam, Jamshid Amiri; Dávila-Céspedes, Antonio; Kehraus, Stefan; Crüsemann, Max; Köse, Meryem; Müller, Christian; König, Gabriele M.

doi:10.3390/md16100369

Cited by 29 publications

(25 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is an exciting avenue to exploit for potential therapeutics (Kenakin, 2018), and the chemokine receptors are examples of immune-expressed GPCRs with multiple endogenous biased ligands (Rajagopal et al, 2013). Synthetic biased agonists at GPR84 have been identified (Pillaiyar et al, 2017(Pillaiyar et al, , 2018Moghaddam et al, 2018), and recent work by Lucy et al (2019) has shown that G-protein-biased DL-175 has a diminished chemoattractant effect on human myeloid cells, while maintaining levels of phagocytosis enhancement.…”

Section: Multiple Physiological Ligandsmentioning

confidence: 99%

20 Years an Orphan: Is GPR84 a Plausible Medium-Chain Fatty Acid-Sensing Receptor?

Luscombe

Lucy

Bataille

et al. 2020

DNA and Cell Biology

View full text Add to dashboard Cite

GPR84 is an inflammation-induced receptor highly expressed on immune cells, yet its endogenous ligand is still unknown. This makes any interpretation of its physiological activity in vivo difficult. However, experiments with potent synthetic agonists have highlighted what the receptor can do, namely, enhance proinflammatory signaling and macrophage effector functions such as phagocytosis. Developing drugs to block these effects has attracted interest from the scientific community with the aim of decreasing disease activity in inflammatory disorders or enhancing inflammation resolution. In this review, we critically reassess the widely held belief that the major role of GPR84 is that of being a medium-chain fatty acid (MCFA) receptor. While MCFAs have been shown to activate GPR84, it remains to be demonstrated that they are present in relevant tissues at appropriate concentrations. In contrast to four other ''full-time'' free fatty acid receptor subtypes, GPR84 is not expressed by enteroendocrine cells and has limited expression in the gastrointestinal tract. Across multiple tissues and cell types, the highest expression levels of GPR84 are observed hours after exposure to an inflammatory stimulus. These factors obscure the relationship between ligand and receptor in the human body and do not support the exclusive physiological pairing of MCFAs with GPR84. To maximize the chances of developing efficacious drugs for inflammatory diseases, we must advance our understanding of GPR84 and what it does in vivo.

show abstract

Section: Multiple Physiological Ligandsmentioning

confidence: 99%

20 Years an Orphan: Is GPR84 a Plausible Medium-Chain Fatty Acid-Sensing Receptor?

Luscombe

Lucy

Bataille

et al. 2020

DNA and Cell Biology

View full text Add to dashboard Cite

show abstract

“…strain 011, produced two cyclopropane-containing medium-chain fatty acids (1,2). Apart from inhibiting other bacteria, these compounds showed an inhibitory effect against strains of MDR MRSA LT-1338 and MRSA LT-1334 (2 and 3 mm) [38].…”

Section: Bacteria From Marine Sedimentsmentioning

confidence: 99%

Antibiotics Development and the Potentials of Marine-Derived Compounds to Stem the Tide of Multidrug-Resistant Pathogenic Bacteria, Fungi, and Protozoa

et al. 2020

View full text Add to dashboard Cite

As the search for new antibiotics continues, the resistance to known antimicrobial compounds continues to increase. Many researchers around the world, in response to antibiotics resistance, have continued to search for new antimicrobial compounds in different ecological niches such as the marine environment. Marine habitats are one of the known and promising sources for bioactive compounds with antimicrobial potentials against currently drug-resistant strains of pathogenic microorganisms. For more than a decade, numerous antimicrobial compounds have been discovered from marine environments, with many more antimicrobials still being discovered every year. So far, only very few compounds are in preclinical and clinical trials. Research in marine natural products has resulted in the isolation and identification of numerous diverse and novel chemical compounds with potency against even drug-resistant pathogens. Some of these compounds, which mainly came from marine bacteria and fungi, have been classified into alkaloids, lactones, phenols, quinones, tannins, terpenes, glycosides, halogenated, polyketides, xanthones, macrocycles, peptides, and fatty acids. All these are geared towards discovering and isolating unique compounds with therapeutic potential, especially against multidrug-resistant pathogenic microorganisms. In this review, we tried to summarize published articles from 2015 to 2019 on antimicrobial compounds isolated from marine sources, including some of their chemical structures and tests performed against drug-resistant pathogens.

show abstract

“…showed activity against the oyster pathogen Roseovarius crassostreae [1]. R. crassostreae has an adverse effect on natural oyster populations and on oyster farming operations [5].…”

Section: Data Descriptionmentioning

confidence: 99%

Genome Analysis of the Marine Bacterium Labrenzia sp. Strain 011, a Potential Protective Agent of Mollusks

Moghaddam

Dávila-Céspedes

Alanjary

et al. 2019

Data

Self Cite

View full text Add to dashboard Cite

The marine bacterium Labrenzia sp. strain 011 was isolated from the coastal sediment of Kronsgaard, Germany. The Labrenzia species are suggested to be protective agents of mollusks. Labrenzia sp. strain 011 produces specialized metabolites, which showed activity against a range of microorganisms, thereunder strong inhibitory effects against Pseudoroseovarius crassostreae DSM 16,950 (genus Roseovarius), the causative agent of oyster disease. The genome of Labrenzia sp. strain 011 was sequenced and assembled into 65 contigs, has a size of 5.1 Mbp, and a G+C content of 61.6%. A comparative genome analysis defined Labrenzia sp. strain 011 as a distinct new species within the genus Labrenzia, whereby 44% of the genome was contributed to the Labrenzia core genome. The genomic data provided here is expected to contribute to a deeper understanding of the mollusk-protective role of Labrenzia spp.

show abstract

Cyclopropane-Containing Fatty Acids from the Marine Bacterium Labrenzia sp. 011 with Antimicrobial and GPR84 Activity

Cited by 29 publications

References 63 publications

20 Years an Orphan: Is GPR84 a Plausible Medium-Chain Fatty Acid-Sensing Receptor?

20 Years an Orphan: Is GPR84 a Plausible Medium-Chain Fatty Acid-Sensing Receptor?

Antibiotics Development and the Potentials of Marine-Derived Compounds to Stem the Tide of Multidrug-Resistant Pathogenic Bacteria, Fungi, and Protozoa

Genome Analysis of the Marine Bacterium Labrenzia sp. Strain 011, a Potential Protective Agent of Mollusks

Contact Info

Product

Resources

About